Oncoethix – Series B Financing

Oncoethix SA, the Swiss-based specialist in oncology drug development, has closed a series B financing raising CHF 18 million. SV Life Science (SVLS), a leading international life sciences venture capital firm, led the financing, joined by new investor Edmond de Rothschild Investment Partners.

Lenz & Staehelin advised SVLS as Swiss counsel. The team consisted of Tino Gaberthüel and Dominik Kaczmarczyk.

Published: 31 July 2013